Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting

Archives of Dermatology

Volumn 148, Issue 4, 2012, Pages 487-494

  Gelfand, Joel M ^a,b   Wan, Joy ^a   Callis Duffin, Kristina ^c   Krueger, Gerald G ^c   Kalb, Robert E ^d   Weisman, Jamie D ^e   Sperber, Brian R ^f   Stierstorfer, Michael B ^g   Brod, Bruce A ^a,h   Schleicher, Stephen M ⁱ   Bebo, Bruce F ^j   Troxel, Andrea B ^b   Shin, Daniel B ^a,b   Steinemann, Jane M ^a,k   Goldfarb, Jennifer ^a   Yeung, Howa ^a   Van Voorhees, Abby S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e Peachtree Dermatology Associates   (United States)

^f Dermatologic Surgery Unit   (United States)

^g East Penn Dermatology   (United States)

^h Dermatology Associates of Lancaster   (United States)

ⁱ DermDox Centers for Dermatology   (United States)

^j National Psoriasis Foundation   (United States)

^k DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; METHOTREXATE; USTEKINUMAB;

ADULT; ARTICLE; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; SYSTEMIC THERAPY; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

EID: 84859945883     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.370     Document Type: Article

References (35)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
2. Richardson SK, Gelfand JM. Update on the natural history and systemic treatment of psoriasis. Adv Dermatol. 2008;24:171-196.
3. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586-592.
4. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411-2418.
5. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704-708. (Pubitemid 39516879)
6. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol. 2011;131(5):1007-1010.
7. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741. (Pubitemid 44547793)
8. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000-1006.
9. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41(3, pt 1):401-407. (Pubitemid 29418506)
10. Pariser DM, Bagel J, Gelfand JM, et al National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007; 143(2):239-242. (Pubitemid 46294591)
11. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with wide-spread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2): 136-139. (Pubitemid 38457271)
12. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60(2):218-224.
13. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 4: guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485.
14. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. (Pubitemid 351509656)
15. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults withpsoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035-1050.
16. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol. 2001;58(3):435-440. (Pubitemid 32217460)
17. Menter A, Korman NJ, Elmets CA, et al American Academy of Dermatology Work Group. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 6: guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-174.
18. Naldi L, Svensson A, Diepgen T, et al European Dermato-Epidemiology Network. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol. 2003;120(5):738-741. (Pubitemid 36529071)
19. Naldi L, Svensson A, Zenoni D, et al European Dermato-Epidemiology Network. Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006. Br J Dermatol. 2010;162(2):384-389.
20. Iglehart JK. Prioritizing comparative-effectiveness research-IOM recommendations. N Engl J Med. 2009;361(4):325-328.
21. Enbrel (etanercept) for the treatment of pediatric plaque psoriasis. Food and Drug Administration. June 18, 2008. http://www.fda.gov/ohrms/dockets/ac/08/ briefing /2008-4361b2-01-FDA.pdf. Accessed December 7, 2011.
22. Centocor: briefing document for ustekinumab (CNTO 1275). Food and Drug Administration. June 17, 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing /2008-4361b1-02-CENTOCOR.pdf. Accessed December 7, 2011.
23. Cook D. Clinical review: BLA 125057/110: Humira (adalimumab): adequacy of patient exposure and safety assessments. Food and Drug Administration. http: //www.accessdata.fda.gov/drugsatfda-docs/nda/2008/125057s110-MedR-P2 .pdf. Accessed December 8, 2011.
24. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659-664.
25. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706. (Pubitemid 38405384)
26. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons; 2000.
27. Zhang J, Yu KF. What's the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690-1691. (Pubitemid 28532993)
28. Saurat JH, Stingl G, Dubertret L, et al CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-566. (Pubitemid 351239154)
29. Griffiths CEM, Strober BE, van de Kerkhof P, et al ACCEPT Study Group. Comparison of ustekinumab and etanercept formoderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-128.
30. Humira [package insert]. North Chicago, IL: Abbott Laboratories; 2011.
31. Enbrel prescribing information. Amgen Inc. http://pi.amgen.com/united- states /enbrel/derm/enbrel-pi.pdf. Accessed August 24, 2011.
32. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 5: guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. JAmAcad Dermatol. 2010;62(1):114-135.
33. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? a systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis [published online October 29, 2011]. J Am Acad Dermatol.
34. Spuls PI, Lecluse LLA, Poulsen M-LNF, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis? quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-943.
35. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158(3):549-557. (Pubitemid 351239150)